Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies

Gina Li, Nicolas Bonamici, Mahua Dey, Maciej S Lesniak, Irina V Balyasnikova*

*Corresponding author for this work

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Introduction: Glioblastoma (GBM) is the most aggressive malignant brain cancer in adults, and its poor prognosis and resistance to the existing standard of care require the development of innovative therapeutic modalities. The local delivery of stem cells as therapeutic carriers against glioma has produced encouraging results, but encounters obstacles with regards to the repeatability and invasiveness of administration. Intranasal delivery of therapeutic stem cells could overcome these obstacles, among others, as a noninvasive and easily repeatable mode of administration. Areas covered: This review describes nasal anatomy, routes of stem cell migration, and factors affecting stem cell delivery to hard-to-reach tumors. Furthermore, this review discusses the molecular mechanisms underlying stem cell migration following delivery, as well as possible stem cell effector functions to be considered in combination with intranasal delivery. Expert opinion: Further research is necessary to elucidate the dynamics of stem cell effector functions in the context of intranasal delivery and optimize their therapeutic potency. Nonetheless, the technique represents a promising tool against brain cancer and has the potential to be expanded for use against other brain pathologies.

Original languageEnglish (US)
Pages (from-to)163-172
Number of pages10
JournalExpert Opinion on Drug Delivery
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Brain
Neoplasms
Brain Neoplasms
Cell Movement
Therapeutics
Stem Cell Factor
Expert Testimony
Glioblastoma
Standard of Care
Nose
Glioma
Anatomy
Pathology
Research

Keywords

  • CNS delivery
  • Glioblastoma
  • intranasal delivery
  • malignant glioma
  • stem cells

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{eb09a62c2ef545e8811688553a98137e,
title = "Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies",
abstract = "Introduction: Glioblastoma (GBM) is the most aggressive malignant brain cancer in adults, and its poor prognosis and resistance to the existing standard of care require the development of innovative therapeutic modalities. The local delivery of stem cells as therapeutic carriers against glioma has produced encouraging results, but encounters obstacles with regards to the repeatability and invasiveness of administration. Intranasal delivery of therapeutic stem cells could overcome these obstacles, among others, as a noninvasive and easily repeatable mode of administration. Areas covered: This review describes nasal anatomy, routes of stem cell migration, and factors affecting stem cell delivery to hard-to-reach tumors. Furthermore, this review discusses the molecular mechanisms underlying stem cell migration following delivery, as well as possible stem cell effector functions to be considered in combination with intranasal delivery. Expert opinion: Further research is necessary to elucidate the dynamics of stem cell effector functions in the context of intranasal delivery and optimize their therapeutic potency. Nonetheless, the technique represents a promising tool against brain cancer and has the potential to be expanded for use against other brain pathologies.",
keywords = "CNS delivery, Glioblastoma, intranasal delivery, malignant glioma, stem cells",
author = "Gina Li and Nicolas Bonamici and Mahua Dey and Lesniak, {Maciej S} and Balyasnikova, {Irina V}",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/17425247.2018.1378642",
language = "English (US)",
volume = "15",
pages = "163--172",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "2",

}

Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies. / Li, Gina; Bonamici, Nicolas; Dey, Mahua; Lesniak, Maciej S; Balyasnikova, Irina V.

In: Expert Opinion on Drug Delivery, Vol. 15, No. 2, 01.02.2018, p. 163-172.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies

AU - Li, Gina

AU - Bonamici, Nicolas

AU - Dey, Mahua

AU - Lesniak, Maciej S

AU - Balyasnikova, Irina V

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: Glioblastoma (GBM) is the most aggressive malignant brain cancer in adults, and its poor prognosis and resistance to the existing standard of care require the development of innovative therapeutic modalities. The local delivery of stem cells as therapeutic carriers against glioma has produced encouraging results, but encounters obstacles with regards to the repeatability and invasiveness of administration. Intranasal delivery of therapeutic stem cells could overcome these obstacles, among others, as a noninvasive and easily repeatable mode of administration. Areas covered: This review describes nasal anatomy, routes of stem cell migration, and factors affecting stem cell delivery to hard-to-reach tumors. Furthermore, this review discusses the molecular mechanisms underlying stem cell migration following delivery, as well as possible stem cell effector functions to be considered in combination with intranasal delivery. Expert opinion: Further research is necessary to elucidate the dynamics of stem cell effector functions in the context of intranasal delivery and optimize their therapeutic potency. Nonetheless, the technique represents a promising tool against brain cancer and has the potential to be expanded for use against other brain pathologies.

AB - Introduction: Glioblastoma (GBM) is the most aggressive malignant brain cancer in adults, and its poor prognosis and resistance to the existing standard of care require the development of innovative therapeutic modalities. The local delivery of stem cells as therapeutic carriers against glioma has produced encouraging results, but encounters obstacles with regards to the repeatability and invasiveness of administration. Intranasal delivery of therapeutic stem cells could overcome these obstacles, among others, as a noninvasive and easily repeatable mode of administration. Areas covered: This review describes nasal anatomy, routes of stem cell migration, and factors affecting stem cell delivery to hard-to-reach tumors. Furthermore, this review discusses the molecular mechanisms underlying stem cell migration following delivery, as well as possible stem cell effector functions to be considered in combination with intranasal delivery. Expert opinion: Further research is necessary to elucidate the dynamics of stem cell effector functions in the context of intranasal delivery and optimize their therapeutic potency. Nonetheless, the technique represents a promising tool against brain cancer and has the potential to be expanded for use against other brain pathologies.

KW - CNS delivery

KW - Glioblastoma

KW - intranasal delivery

KW - malignant glioma

KW - stem cells

UR - http://www.scopus.com/inward/record.url?scp=85042556519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042556519&partnerID=8YFLogxK

U2 - 10.1080/17425247.2018.1378642

DO - 10.1080/17425247.2018.1378642

M3 - Review article

VL - 15

SP - 163

EP - 172

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 2

ER -